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Introduction: Successful management of pediatric and adult human immunodeficiency virus
(HIV) disease includes lifelong administration of antiretroviral therapy (ART). The need for the
continuous use of antiretroviral drugs throughout the life course poses a challenge to children,
adolescents, and adults living with HIV and their caregivers. Historically, treatment interruptions
have been viewed as a negative therapeutic strategy. Recently, however, treatment interruptions
or treatment reduction strategies have become a focus of investigations as innovative approaches
to the long-term management of HIV disease. Current challenges with treatment interruptions
include identifying an appropriate timeframe for length of interruptions and identifying HIV
patient populations in whom the treatment interruption can be successful.
Objective: In this review, we aimed at summarizing recent studies of planned and unplanned
treatment interruptions in children and adults living with HIV.
Materials and methods: We searched two databases (PubMed and Cochrane Controlled
Trials Register) using keywords (HIV OR AIDS OR acquired immunodeficiency syndrome
OR HIV-1 OR antiretroviral) AND (treatment interruption OR planned interruption OR
therapeutic interruption OR unplanned interruption), for published randomized and nonrandomized clinical trials and observational cohort studies in children and adults (from birth
to 99 years of age) in global settings covering a period from 2012 to 2018. In this review,
only the studies that contained pediatric and adolescent populations with baseline immunological, virological, and clinical characteristics and outcomes after treatment interruption
were included.
Results: A total of 174 eligible citations from the two databases were identified. We identified
10 prospective treatment interruption studies on children (five studies) and adults (five studies) during 2012–2018 with a total of 863 pediatric and 273 adult subjects. Collectively, recent
studies on children and adults with HIV infection suggest that treatment interruptions with
proper monitoring can be successful by instituting well-defined immunological and virological
parameters or thresholds such as CD4 count, CD4%, and HIV RNA viral load that identify lowrisk populations with treatment failure. In addition to standard virological and immunological
outcome measurements, selected biomarkers that help detect early immune activation may also
be useful in the monitoring of treatment interruption.
Conclusion: Treatment interruptions in adult and especially pediatric patients with wellcontrolled HIV disease may provide an alternative opportunity to optimize long-term HIV
management by minimizing drug-associated toxicity and improving long-term adherence and
quality of life.
Keywords: HIV, antiretroviral therapy, treatment interruptions
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as they demonstrated quick recovery of the CD4 count and
viral suppression in comparison to groups of children on
continuous ART.7 Our review of the recent literature on ART
interruptions in children and adults evaluated virological and
immunological outcomes in populations with suppressed
and unsuppressed HIV infection and the impact of treatment
interruption on HIV transmission.

More than 34 million adults and 1.8 million children are
estimated to be living with human immunodeficiency virus
(HIV) globally with the majority living in sub-Saharan
Africa.1 The number of newly infected adults has declined
worldwide by 30% between 2000 and 2015, and in children
aged <15 years, it has declined even further by 69%.1 There
were still an estimated 2.1 million new HIV infections in
2015, and the global coverage with antiretroviral therapy
(ART) remained low at 49% despite significant global
investment in the AIDS response that has increased from 5
to 19 billion during the first 15 years of our current century.1
Although the global scale-up of antiretroviral drug access,
health system strengthening, and community initiatives
has proven successful in improving HIV treatment through
increased access to medication, counseling, support groups,
and behavioral interventions, unplanned treatment interruptions continue to occur among populations living with
HIV.2 Multiple challenges contribute to unplanned treatment
interruptions in infants and adults. Adherence challenges
in infants and children include issues with palatability,
swallowability, and dispensability of antiretroviral drugs.3
In adolescents and adults, adherence challenges more
frequently include adverse events, discrimination, lack of
confidentiality, treatment costs, and provider-associated
factors such as distance to point of care, limited face-toface counseling, and lack of trust.4 As optimal treatment of
HIV is aimed at preventing viral replication and suppressing
the viral load, avoiding unplanned treatment interruptions
can decrease the likelihood of sustained detectable viral
load, generating drug resistance and causing a decline in
CD4 cells.
Historically, treatment interruptions have been viewed
as a negative therapeutic strategy following the findings of
the Strategies for Management of ART (SMART) study,
where episodic ART guided by CD4 cell count in adults
resulted in the rise of opportunistic infections, death, and a
decrease in the quality of life compared to continuous ART.5
Other adult studies have shown that prolonged interruption
of ART increases the risk of adherence failure once ART
is reintroduced, thus potentially increasing the risk of HIV
transmission.6 These findings have led to a decreased interest to conducting such studies in adults. Recently, treatment
interruptions or treatment reduction strategies continue to
be investigated as a novel approach to the long-term management of HIV disease. Moreover, several structured ART
interruption studies in children displayed favorable results
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Materials and methods
We searched two databases (PubMed and Cochrane Controlled Trials Register) covering a period from 2012 to 2018
for all the available randomized and nonrandomized clinical
trials and observational cohort studies globally. Only data
from completed or published studies were used in this review.
No abstracts were included in the review.
Using search keywords (HIV OR AIDS OR acquired
immunodeficiency syndrome OR HIV-1 OR antiretroviral)
AND (treatment interruption OR planned interruption OR
therapeutic interruption OR unplanned interruption), a
total of 174 eligible citations from the two databases were
identified. Exclusions included the following: abstracts,
animal studies, editorials, opinions, nonclinical studies, and
studies without data. The selected studies were classified
into child (birth to <18 years of age) and adult (18 years
and older) categories. A total of 10 prospective trials and
studies were selected for our review. Outcome measures
in our review and analysis included the following: immunological outcomes such as the change in CD4 cell count
and CD4%; virological outcomes such as the change in
plasma HIV RNA viral load and log10, changes in HIV
drug resistance; and clinical outcomes such as death and
progression of HIV disease.
The search included the quality studies that collected data
in pediatric subjects starting at birth and adults to 99 years
of age who had undergone treatment interruption in which
immunological parameters were collected to evaluate treatment interruption. Both authors independently evaluated
each of the studies from the search. Only the studies that
included target populations, baseline characteristics, and
immunological, virological, and clinical outcomes of treatment interruption were included.

Results
Treatment interruptions in infants and
children living with HIV
We have identified five treatment interruption studies in
children during 2012–2018 with a total of 863 participants
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(Table 1). The Children with HIV Early anti-Retroviral
(CHER) trial evaluated the strategies for deferred ART initiation in infants and young children compared to the early
start and further interruption of ART at 40 and 96 weeks of
treatment.8 In the CHER trial, 377 infants from South Africa
were randomly allocated to one of the three groups: deferred
ART, immediate ART for 40 weeks, or immediate ART for
96 weeks with subsequent treatment interruption. The results
showed that virological failure, defined as HIV RNA viral
load of >10,000 copies/mL after 24 weeks on ART, was more
frequent in the ART deferred group, occurring in 10 children
(8%) in comparison to one child each (<1%) in the groups
that underwent treatment interruptions at 40 and 96 weeks
on ART.8 Primary outcome of death was considerably higher
in the ART deferred group compared to the groups that
were started on ART and underwent treatment interruption,
occurring in 21 children (16%) in the ART deferred group,
and in 11 (8%) and 9 (7%) children in the 40 and 96 weeks
treatment interruption groups.8 Failure due to ART toxicity
did not occur in any child in the study.8 Time to restarting ART
after treatment interruption ranged from 33 weeks (26–45)
in the group that stopped ART after 40 weeks to 70 weeks
(35–109) in those who were on ART for a longer period of 96
weeks. After 4.8 years at the end of the trial, 19% of children
who stopped after 40 weeks and 32% of children who stopped
ART after 96 weeks remained off ART.8 While the primary
aim of the CHER trial was to evaluate the strategies for the
initiation of ART in pediatric participants, its treatment interruption data suggested no evidence of excess disease progression during subsequent treatment interruption and with less
overall ART exposure in those children who started early on
treatment. CHER trial data also support the hypothesis that
longer time on primary ART may permit longer subsequent
interruption without compromising immunological, clinical,
and virological outcomes.8
In the Optimizing Pediatric HIV-1 Therapy 03 (OPH-03)
study, 121 infants from Kenya younger than 13 months of
age were initiated on ART and 75 (62%) of infants completed at least 24 months of ART therapy.9 Of those who
completed 24 months of ART, 42 children were randomized
to either the planned treatment interruption or continuous
ART arms.9 Of the 21 children in the treatment interruption
group at 3 months post randomization, the median CD4%
decreased from 34% to 23%, and 14 (66%) children met the
ART restart criteria. The median CD4 cell count in those
children restarting ART was not statistically significant as
it decreased from 1390 to 1365 cells/μL.9 Interestingly, in
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the continuous ART arm, one-third (35%) of children contained an elevated HIV RNA viral load of >1000 copies/
mL at 3 months of treatment. After 18 months following the
randomization and 15 months following the restart of ART,
of the 14 children who met the restarting criteria, there were
no significant differences in CD4% between both arms.9
Growth, measured as z-scores for weight for age, weight
for height, and height for age, also showed no significant
differences at 18 months post randomization.9 Only seven
children in the treatment interruption group remained off
ART longer than 5 months, and the data safety and monitoring board (DSMB) had recommended that randomization
should be stopped due to the short durability of treatment
interruption.9 Short treatment interruption in this pediatric
study did not appear to compromise the 18-month outcomes
including CD4%, viral suppression, child’s growth, or
morbidity compared to continued ART among infants who
started early ART.
In the Pediatric European Network for Treatment of
AIDS (PENTA 11), a multi-country and multiregional trial,
children with undetectable HIV RNA viral load of <50
copies/mL and CD4% of at least 30% (2–6 years), or CD4
count of at least 500 cells/μL (7–15 years) were randomized to continuous ART or planned treatment interruption
and were recommended to resume ART at the end of the
trial.7 A total of 101 children (51 on continuous ART and
50 who experienced treatment interruption; with a median
baseline age of 9.2 years) participated in the long term with
a median duration of 4.6 years of follow-up. At baseline,
prior to randomization, the median CD4% was 37%, and
the median CD4 cell count was 970 cells/μL.7 After 2 years,
the difference in CD4% between the treatment interruption
and continuous ART arms was small with overlapping 95%
CIs for both study groups. The median CD4% was 32%,
and the CD4 cell count was 792 cells/μL in children who
experienced treatment interruptions compared to the median
CD4% of 36% with a CD4 cell count of 927 cells/μL in
children on continuous ART.7 The percentage of children
with an HIV RNA viral load of <50 copies/mL decreased
in both groups by the end of the study period: from 94%
to 76% in the continuous treatment arm and from 86% to
60% in the treatment interruption arm.7 A total of 15 out of
50 children in the treatment interruption arm experienced
a second treatment interruption, but none had a third interruption of ART.7
In our published study, we have retrospectively collected
data from a perinatal cohort of 136 children and adolescents
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Table 1 Studies evaluating TI in children and adults
Study identifier
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Pediatric studies
NCT00102960
(CHER)8

NCT00428116
(OPH-03)9

ISRCTN 36694210
(PENTA 11)7

UO1 AI6950303S210

ISRCTN 97755073
(PENTA 16
BREATHER)11

Adult studies
ISRCTN 75856952
(STOPAR)13,14

ISS-PART15

Substudy of ACTG
5170 trial16

Study

Eligibility criteria

TI duration/number of
subjects

End point

Open trial in HIV-infected infants
<12 weeks randomized (1:1:1) to
deferred ART, immediate ART for 40
or 96 weeks followed by TI to assess
time to failure of first-line ART via
immunological, clinical, and virological
parameters or death
Randomized trial in children with
chronic HIV infection on ART that
was started at <13 months of age
and completed at least 24 months of
treatment before randomization to
the TI group versus continuous ART
A Phase II, multicenter, open
randomized trial in children aged
2–15 years with chronic HIV infection
on any antiretroviral regimen
containing three or more drugs
undergoing planned TI
Retrospective study of a larger
longitudinal cohort study of children
and adolescents with HIV to assess
immunological and virological
parameters in subjects who
experienced TI
Open, randomized, international, noninferiority trial evaluating the efficacy
of efavirenz-based ART on short
cycles of 5 days on and 2 days off in
maintaining virological suppression

Infants 6–12 weeks
CD4%: >25%

TI duration: 16–109 weeks
until CD4% <25%
Subjects: n=377

HIV RNA viral load,
CD4%, death

Infants <13 months of age
CD4%: >25%
Normal growth

TI duration: 18 months
Subjects: n=140

HIV RNA viral load,
CD4 count, CD4%,
growth

Children 2–15 years
Viral load (HIV RNA viral
load): <50 copies/mL
CD4%: >30% (2–6 years)
CD4 cell count: >500
cells/μL (7–15 years)
Children and adolescents:
0–24 years

TI duration: 24 months
Subjects: n=109

HIV RNA viral load,
CD4 count, CD4%,
lipids

TI duration: >4 weeks
Subjects: n=38

HIV RNA viral load,
CD4 count, CD4%

Children and adolescents
8–24 years
HIV RNA viral load:
<50 copies/mL for
>12 months CD4 cell
count: >350 cells/μL

Duration: 48 weeks
Subjects: n=199

HIV RNA viral load,
CD4 count, CD4%,
disease progression,
HIV drug resistance, and
drug toxicity

Randomized, open-label, multicenter
study in adults with chronically
suppressed HIV >18 years of age
assessed genotypic resistance, shortand long-term clinical and immunological
consequences following staggered TI
where NNRTIs were discontinued
7 days before the nucleoside reversetranscriptase inhibitors
Randomized study in chronically
HIV-suppressed adults comparing the
outcomes of 2 years of PTIs versus
continued ART at five periods in time
(1, 1, 2, 2, and 3 months) separated
by 3 months of therapy between each
period
Observational prospective study
in chronically suppressed and
unsuppressed adults with HIV
investigated the impact of NAbs
on CD4 T-cell count and viral load
in a cohort of ART recipients who
underwent extended structured TI

Adults >18 years
HIV RNA viral load:
<50 copies/mL
CD4 count: >500 cells/μL

TI duration: median of
183 days with nadir CD4 cell
count of <200 cells/μL and
463 days with nadir CD4 cell
count of 200–350 cells/μL
Subjects: n=106

Genotypic resistance,
disease progression,
virological failure,
immunological failure

Adults 32–57 years old
HIV RNA viral load:
<50 copies/mL before
first PTI
Detectable viral load
during PTI

TI duration: 1, 2, and
3 months
Subjects: n=12

CCR5 tropism, HIV
RNA viral load, CD4
count

Adults >18 years
HIV RNA viral load:
<55,000 copies/mL
CD4 count >350 cells/μL

TI duration: 96 weeks
Subjects: n=50

NAbs, CD4 count, HIV
RNA viral load

(Continued)
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Table 1 (Continued)
Study identifier

Study

Eligibility criteria

TI duration/number of
subjects

End point

ANRS 116
SALTO17

Secondary analysis of multicenter
study with participants on stable
cART regimen, with HIV RNA viral
load of 5000 copies/mL for at least
6 months and a CD4 cell count above
450 cells/μL at TI. For the secondary
analysis, participants on triple-drug
ART with HIV RNA viral load below
400 copies/mL were selected for
PTI and monitored (week 2, months
1, 2, 4, and 6, and every 3 months
thereafter, until month 36 to
determine whether HIV replication
can be controlled following PTI
started early in the course of
infection
Analysis of 10 participants with
chronically suppressed HIV who
participated in a passive antibody
transfer study, where human
monoclonal antibody (VRC01) was
administered intravenously 3 days
before and 14 and 28 days after
discontinuation of ART

Adults >18 years
HIV RNA viral load:
<400 copies/mL
CD4 count >450 cells/mL

TI duration: 36 months
Subjects: n=95

HIV RNA viral load

Adults >18 years
HIV RNA viral load:
<40 copies/mL

TI duration: median of
57 days (range of 22–
115 days)
Subjects: n=10

HIV RNA viral load,
CD4 count

Cohort of
A5340 and
NIH15-I-014018

Abbreviations: ACTG, AIDS Clinical Trials Group; ANRS, Agence Nationale de Recherche sur le Sida; ART, antiretroviral therapy; CHER, Children with HIV
Early anti-Retroviral; HIV, human immunodeficiency virus; ISS-PART, Istituto Superiore di Sanità-Pulsed ART; NAbs, neutralizing antibodies; NNRTI, non-nucleoside
reverse-transcriptase inhibitor; OPH-03, Optimizing Pediatric HIV-1 Therapy 03; PENTA, Pediatric European Network for Treatment of AIDS; PTI, planned treatment
interruption; TI, treatment interruption.

in the US and identified 38 children who experienced
planned and unplanned treatment of at least 4 weeks of
duration within the settings of routine clinical care.10 Median
treatment interruption lasted 0.98 years with a range between
0.4 and 2.4 years. The median CD4 count and CD4% were
lower in children and adolescents who experienced treatment interruptions in comparison to those on continuous
ART. The median CD4 count, CD4%, and HIV RNA viral
load prior to treatment interruption were 789 cells/μL, 27%,
and 2362 copies/mL, respectively.10 In the same cohort of
children prior to restarting ART, the median CD4 count,
CD4%, and HIV RNA viral load were 493 cells/μL, 22%,
and 52,002 copies/mL. After a median time of 1.8 months
following the restart of ART in children who experienced
treatment interruption, the CD4 count and CD4% increased
to 613 cells/μL and 26%, respectively, while HIV RNA viral
load decreased to 2510 copies/mL.10 Of the 38 children
who experienced t reatment interruption, six (15%) children
experienced at least one additional episode of treatment
interruption.10

HIV/AIDS - Research and Palliative Care 2018:10

The PENTA 16 BREATHER trial was an open, randomized, international, non-inferiority trial evaluating the efficacy
of efavirenz-based ART on short cycles of 5 days on and
2 days off in maintaining virological suppression in 199
children and adolescents aged 8–24 years who were followed
for 48 weeks.11 Prior to initiating the trial, participants must
have been on a stable continuous ART with an HIV RNA viral
load of <50 copies/mL for the previous 12 months. Of the
99 participants randomized to short-cycle ART and 100 on
continuous ART, 157 (79%) participants were 8–17 years of
age, 42 (21%) were 18–24 years of age, and 185 (93%) of participants completed all scheduled visits up to week 48.11 The
primary endpoint evaluating virological failure, defined as
HIV RNA viral load of >50 copies/mL by 48 weeks, showed
no differences as it occurred in six participants in the shortcycle ART group and seven in the continuous ART group.
Of the eight participants in the short-cycle group in whom
the ART regimen was changed, six were due to virological
failure, one due to an adverse event, and one due to compliance issues. Major non-nucleoside reverse-transcriptase
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inhibitor (NNRTI) mutations occurred in seven participants
experiencing virological failure (two in the short-cycle group
and five in the continuous ART group).11 No significant CD4
count or CD4% differences occurred between both groups.11
No differences occurred between groups in the evaluation of
grade 3/4 adverse events or serious adverse events.11 Overall,
the trial showed non-inferiority of short-cycle therapy and
continuous ART with similar safety results.
Overall, despite expected declines in the CD4 cell counts
and rise in HIV viral load accompanying treatment interruption, reviewed pediatric studies on the treatment interruption
of ART did not appear to cause significant compromise of
immunological or virological outcomes 1–2 years following
treatment interruption. No increase in deaths was reported in
the treatment interruption cohorts of any study compared to
the continuous ART cohorts. Further, children in the PENTA
11 planned treatment interruption and continuous treatment
arms performed similarly on neurocognitive assessments
evaluating information processing speed, sustained attention,
short-term memory, and quality-of-life scores, suggesting
the lack of the long-term effect on the pediatric neurodevelopmental milestones.12

Treatment interruptions in adults living
with HIV
We have identified five treatment interruption studies in adults
during 2012–2018 with a total of 273 subjects (Table 1).
The STOPAR study, a randomized, open-label, multicenter
study in adults with chronically suppressed HIV assessed
genotypic resistance and short- and long-term clinical and
immunological consequences following staggered treatment
interruption.13,14 STOPAR study participants had a median
CD4 cell count of 845 cells/μL, CD4 cell nadir count of 344
cells/μL, and HIV RNA viral load of <50 copies/mL prior to
being randomized to either continuous ART or the planned
staggered treatment interruption arm.13,14 Staggered treatment
interruption was defined as restarting ART once the CD4 cell
count dropped below 350 cells/μL or the occurrence of any
significant clinical event (B or C disease in Center for Disease
Control classification), and then re-interrupting ART again
once the CD4 cell count reached 500 cells/μL and the HIV
RNA viral load was undetectable at <50 copies/mL.14 In this
study, the CD4 cell count progressively declined in the treatment interruption cohort (56 participants) compared to the
continuous ART cohort (50 participants) over the course of the
study; median CD4 cell counts at three different time intervals
(48, 96, and 144 weeks) were 546, 493, and 480 cells/μL in the
treatment interruption cohort and 796, 783, and 772 cells/μL
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in the continuous ART cohort.14 Therapeutic failure, defined
as CD4 cell count of <200 cells/μL (immunological failure),
or maintaining a viral load of >1000 copies/mL for 6 months
after restarting treatment (virological failure), or a viral load
of >50 copies/mL performed on two separate occasions
(virological rebound), occurred in seven (14%) participants
in the continuous ART cohort and 15 (27%) participants in
the treatment interruption cohort.14 Of note, 10 participants
(20%) in the continuous ART cohort required modification
in ART due to ART drug toxicity, while there were no ART
modifications in the treatment interruption cohort.14 There
were no deaths in the treatment interruption cohort, and 27
participants (48%) did not receive ART throughout the entire
study.14 Seven participants exhibited emerging HIV resistance
mutations following treatment interruption with M184V
mutation being the most common as it occurred in three
participants.13 Among participants with repeated treatment
interruptions, no new HIV resistance mutations appeared
compared to the first genotypic resistance testing.13
The Istituto Superiore di Sanità-Pulsed ART (ISS-PART)
was a randomized study in chronically HIV-suppressed adults
comparing immunological and virological outcomes in adults
undergoing multiple treatment interruptions versus continuous
ART over 2 years. Throughout the study, repetitive treatment
interruptions consisting of 1, 1, 2, 2, and 3 months were
separated by 3 months of consecutive ART between each interruption period.15 All participants in the ISS-PART study had
HIV RNA viral load of <200 copies/mL and a median CD4
cell count of 664 cells/μL prior to treatment interruption.15 All
participants experienced reactivation of the viral replication
(HIV RNA viral load) during treatment interruptions and the
CD4 counts ranged from 363 to 836 cells/μL.15 Evaluation
of HIV RNA viral load following treatment interruptions at
1 and 2 months showed a return to baseline virological suppression at 1 month after restarting ART in most participants.15
Planned treatment interruptions lasting 3 months did not show
a consistent return to suppressed viral load in most participants
compared to shorter treatment interruptions of 1 and 2 months
of duration.15 Changes in CCR5 tropism were not associated
with increased viral load or development of other HIV resistance mutations following treatment interruptions.15
The AIDS Clinical Trials Group (ACTG) 5170 trial was
a multicenter observational prospective study in adults with
HIV which investigated the impact of neutralizing antibodies
(NAbs) on CD4 cell count and viral load in a cohort of adults
receiving ART who underwent treatment interruption.16 For
the sub-study, 50 of 167 participants who exhibited a CD4
cell count decline 24 weeks following treatment interruption
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were selected, and 38 (76%) were present throughout the
entire 96 weeks of the sub-study.16 The median CD4 cell
count at study initiation was 855 cells/μL and HIV RNA viral
load ranged from <50 to 12,441 copies/mL. At the end of the
study period, the median CD4 cell count was 454 cells/μL
with a mean HIV RNA viral load of 4.27 log10 copies/mL.16
The ACTG 5170 sub-study also divided the participants into
progressors (>40% reduction in CD4 cell count through week
24) and non-progressors (no more than a 20% decline), and
the mean log10 viral loads in both groups were comparable at
the conclusion of the study period.16 In the progressor cohort,
nine of 25 participants restarted ART therapy before study
conclusion as their CD4 cell count fell below 250 cells/mL,
while none of the participants in the non-progressor cohort
restarted ART throughout the study period.16
The French National Agency of Research on AIDS (ANRS)
116 SALTO trial was a prospective, open-label, multicenter
trial in adults with stable continuous ART who underwent
treatment interruptions.17 A secondary analysis of participants
on triple-drug ART with HIV RNA viral load below 400 copies/mL was selected for treatment interruption and monitored
(week 2, months 1, 2, 4, and 6, and every 3 months thereafter,
until month 36) to determine whether HIV replication can be
controlled following treatment interruption that was started
early in the course of infection.17 The study included 95 participants with a median CD4 cell count of 813 cells/μL, CD4
nadir cell count of 382 cells/μL, and HIV RNA viral load of
<400 copies/mL prior to planned treatment interruption. Viral
load of participants at 12 months on treatment interruption was
still <400 copies/mL in seven participants and viral suppression
<400 copies/mL lasted up to 36 months in four participants.17
From the A5340 and NIH15-I-0140 studies, which evaluated the safety, pharmacokinetics, and antiviral activity of
the human monoclonal antibody (VRC01), 10 subjects with
chronically suppressed HIV were selected where VRC01 was
administered intravenously 3 days before and 14 and 28 days
after discontinuation of ART.18,19 The median CD4 cell count
was 724 cells/μL, CD4 nadir cell count was 345 cells/μL, and
HIV RNA viral load was <40 copies/mL prior to planned
treatment interruption with three doses of VRC01.18 The
median duration before restarting ART, which was defined
as a decrease of >30% in baseline CD4 count, CD4 count
of <350 cells/μL, or HIV RNA viral load of >1000 copies/
mL for >2 weeks was 57 days with a range of 22–115 days.18

Discussion
Although significant advances in pediatric HIV drug development have been made, current antiretrovirals medications do
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not ensure efficient coverage for HIV-infected children due
to a limited number of pediatric formulations, palatability
and pill size challenges for many ARVs, and few incentives
for drug manufacturers to develop new formulations as the
number of children with HIV continues to decline worldwide.3 Treatment interruptions in children with HIV are
currently not recommended due to the concern for morbidity
and mortality as disease progression in infancy is rapid and
young children under 3 years of age are at an increased risk
of dying from HIV.20 The CHER trial results have brought a
new prospective to the management of pediatric ART after
demonstrating that infants started on ART early in life tolerated planned treatment interruption of their ART well, and
displayed better immunological and clinical outcomes compared to the infants with deferred start of ART.21 Although
the other pediatric treatment interruption OPH-03 study
was stopped after 14 of 21 infants had to restart ART within
3 months based on the restart criteria, it provided reassuring
data on the 18-month outcomes of children who experienced
treatment interruptions. The study also showed a lack of
significant consequences from short-term discontinuation of
ART and provided important insight into the design of future
treatment interruption trials for children.
With the current scale-up of the point-of-care viral load
monitoring, treatment interruption in children with early successful ART may prove a practical alternative, particularly in
perinatally infected children who were started on ART early
after the diagnosis and demonstrated sustained virological
suppression. The PENTA 11 study has demonstrated that with
proper follow-up, treatment interruptions can be safe and
produce fast immunological recovery especially in younger
children (2–6 years of age).7 The study also noted differences
of CD4 naive and memory cell populations in comparison to
adults. Although in adults upon ART initiation changes first
occur in CD4 memory cells followed later by an increase in
naive cells, the reconstitution in children follows a different
pattern where an increase in CD4 memory cells is derived
from the naive pool.22 This implies that although CD4 cell
count decline occurs during treatment interruption, a balance
is achieved and maintained in both CD4 memory and naive
compartments, thus ensuring that treatment interruptions can
be successful in children.22
Currently, we anticipate that the high effectiveness and
tolerability of integrase inhibitor-based ART will significantly
facilitate the daily management of HIV by the children and
their caregivers and may potentially eliminate the need for
treatment interruption consideration. However, we may
also argue that other efficient and better tolerated ARVs
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i ntroduced over the past few years have not removed the need
for daily drug intake and will therefore continue to pose the
consideration for treatment interruptions in the future. Our
observational longitudinal cohort study of children and adolescents with HIV has confirmed long-term negative effect
of unplanned treatment interruptions on immunological and
virological outcomes among perinatally infected children
and adolescents.10 Our study further emphasized that nonadherence and ARV drug toxicity remain major challenges
to the uninterrupted ART in pediatric populations.10 Finally,
high rates of non-adherence to ART among adolescent
populations in our and other published studies lead to the
high rates of unplanned treatment interruptions lasting from
weeks to months among these high-risk populations.23 The
results of the BREATHER study highlight the need to address
planned treatment interruption of ART among adolescents
as a potential alternative strategy to decrease non-adherence
rates, treatment fatigue, and avoiding the undisclosed and
unplanned discontinuation of ART.
For adults living with HIV, earlier treatment interruptions
studies such as the SMART trial have closed the door on
treatment interruption consideration for several years. The
SMART trial offered treatment interruption to adults with
CD4 cell counts of >350 cells/mL and reintroduction of ART
when the CD4 cell count was <250 cells/μL. Due to a higher
risk of opportunistic infections and death, the SMART trial
was discontinued prior to completion.5 Other large adult studies such as the Long-Term Treatment Interruption (LOTTI)
trial had more favorable results on treatment interruptions
with regard to AIDS defining events when applying a higher
threshold of CD4 cell count of >700 cells/mL to start planned
treatment interruption and restarting ART when the CD4 cell
count was <350 cells/mL.24 Despite significant advancements
in the development of effective and tolerable fixed-dose formulations of ARVs for adults in the past decade, however, the
issue of treatment interruption has not become irrelevant to
adult HIV care and treatments. Recently published PSITAR
cohort study results reemphasizes why treatment interruption
is a viable alternative in the right population as it reported
ART modification in 68 of 277 participants with recently
diagnosed HIV during the first year of therapy with the main
reason for discontinuation of therapy being intolerance or
toxic effects of medication (64%), followed by provider’s
decision (16%) and treatment failure (10%).25
The results of the STOPAR study also provided new
evidence for the feasibility of treatment interruptions in
adults living with HIV as almost half of the adults did not
have to restart ART for >3 years, no patients experienced a
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clinical failure or serious adverse event, and all participants
maintained a CD4 count of >350 cells/μL.14 Despite overall
positive results, although investigators of this successful trial
discouraged the use of treatment interruption due to severe
immunological decline in several participants with a baseline
high CD4 cell count, it should be noted that several of those
participants had a low CD4 cell nadir count.14 It is plausible
to consider whether adults with a high CD4 count and a high
CD4 nadir count could be good candidates for treatment
interruption, while those with low CD4 cell nadir might not
be eligible candidates for planned and controlled discontinuation of ART. The results of the adult studies also generated
the question on whether the adults who tolerated treatment
interruptions well the first time and achieved a high CD4
cell count with undetectable viral load after reintroduction
of ART with no change in their genotypic resistance testing
are eligible candidates for subsequent treatment interruptions.
Other adult studies, such as the ISS-PART, which evaluated pulsatile interruption of ART with 3-month periods
of treatment in between and the sub-cohort of the A5340/
NIH15-I-0140, which evaluated length of treatment interruptions following the administration of VRC01, have
shown prolonged time required to return to baseline viral
suppression once ART was restarted.15,18 This is an important
aspect to consider in adults with high rebound in viral load
during treatment interruptions as these populations would
differ from the non-progressor cohorts in the 5170 trial and
the SALTO study (Table 1), where the participants with
low or undetectable viral load during treatment interruption
were capable to tolerate interruptions for an extended time
period.15–17 The ISS-PART study also did not show the relationship between the development of negative CCR5 tropism
and increase in viral load during planned treatment interruption as there was no association between CCR5 tropism
change and accumulation of the HIV resistance-associated
mutations.15
Another important aspect in considering treatment
interruption includes its potential to improve the person’s
quality of life. The PENTA 16 BREATHER study of structured weekend-based treatment interruption in adolescents
showed a preference for structured treatment interruptions
and satisfaction with the clinical trial experience and planned
treatment interruptions among young people as well as noninferiority in comparison to continuous ART and similar
safety results.11 Other studies in adults such as the Options
in Management with Antiretrovirals (OPTIMA), which
was a randomized trial that included 368 adult participants
also showed reassuring results as there was no difference in
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health-related quality of life between the planned treatment
interruption and continued ART cohorts after a median of
3 years of follow-up.26
An important aspect to consider in the management of
HIV is transmission of the virus from mother to child and
horizontally. Treatment interruptions during pregnancy and
breastfeeding have not been considered to be a good option
due to the high risk of mother-to-child transmission along
with high infant and young child mortality associated with
HIV. For the horizontal transmission of HIV, planned treatment interruptions may improve adherence, increase the use
of condoms, decrease unplanned ART interruptions, and
therefore provide the benefit of decreasing transmission of the
virus. A study by Cohen et al,27 where 1763 participants with
HIV were randomized to receive early versus delayed ART
and followed for 5 years along with their partners showed a
93% lower risk of linked partner infection than delayed ART
(three in early ART, 43 in delayed ART).27 Another study that
involved 3381 discordant couples in which one partner was
seropositive for both HIV-1 and herpes simplex virus type
2, and their HIV-1 seronegative partners, showed that 66
(70%) of 94 transmissions occurred when the viral load was
>50,000 copies/mL, even if the CD4 count was >200 cells/μL.28
HIV preexposure prophylaxis that was studied in 4747 HIV-1
sero-discordant heterosexual couples in Uganda and Kenya
(Partners PrEP trial) showed high efficacy of 67% and 75% for
ART (tenofovir or tenofovir–emtricitabine) when compared to
placebo alone.29 Reduction in HIV-1 viral load combined with
increased condom use may also help with decreased horizontal
HIV transmission.30 Early ART initiation with baseline CD4
count of >350 cells/μL has also been shown to decrease the
risk of HIV transmission by 90% in a study in Cote d’Ivoire.31
Overall, the rate of horizontal HIV transmission is lower when
the CD4 count is high and the viral load is low. As HIV viral
load increases during treatment interruptions, an increase in
barrier protection such as condoms is needed to decrease the
potential increase in the rate of HIV transmission.
Based on our review of recent studies, we conclude that
treatment interruptions can be successful in both children and
adults by identifying participants with reassuring stable or
excellent immunological and virological parameters. Clearly,
populations with high viral load, low CD4 cell count, and
multiple chronic conditions cannot be considered for treatment interruptions due to their increased risk of not tolerating
treatment interruptions. For the adult population, participants
with a high CD4 cell count (>500 cells/μL), high CD4 nadir
count, and undetectable viral load who have been chronically
suppressed are at a lower risk of treatment interruption not
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being successful. Subjects with early treatment following
diagnosis are also good candidates for treatment interruptions
as generally they can maintain a low viral load for longer
periods of time. Subjects with a high CD4 count but low
nadir count who are chronically suppressed can still be considered for treatment interruption if there is close follow-up
as they are at a higher risk of viral rebound. However, if the
subject does not appear to be a good candidate for treatment
interruption or if they have not tolerated previous planned or
unplanned treatment interruptions, then management should
focus on maintaining adherence to ART as it will decrease
the risk of opportunistic infections, death, progression to
AIDS, and non-AIDS complications such as HIV-associated
kidney disease, neurologic, and cardiovascular disease among
many others.
Children appear to be better candidates for treatment
interruption than adults as they are generally started on
ART early in the course of the disease due to early diagnosis of perinatally acquired HIV. Children also have a lower
prevalence of other chronic comorbidities associated with
adults such as cardiovascular, renal, and hepatic diseases.7
More prospective pediatric treatment interruption studies
are needed, and they not only can help identify best strategies for long-term management of HIV in children, but can
also help advance our understanding of the best approaches
to treatment interruption and simplification of ART among
adults living with HIV.
Finally, the importance of treatment interruptions as a
strategy in HIV management has become significant in recent
years as we redefine our definitions of HIV cure in the absence
of complete eradication to include sustained virological
remission following the discontinuation of ART.32 Following a critical step of early initiation of ART, other different
therapeutic strategies such as latency-reversing therapy, use
of broadly NAbs, and therapeutic HIV vaccines are being
considered along with planned treatment interruptions and
discontinuations. Treatment interruptions can help determine
whether an individual is in HIV remission and requires close
monitoring and prompt resumption of ART with the rebound
of HIV viral load to prevent development of unfavorable
immunological and clinical consequences. Due to the uncertainty of an HIV cure as we are in the discovery phases of
research,32 treatment interruptions provide a feasible alternate
option in the management of HIV.

Conclusion
Although earlier ART studies led to the recommendations
against planned treatment interruptions in participants
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on ART, the quest for this consideration in the long-term
management of this lifelong health condition remains. The
growing body of literature on treatment interruption studies
from clinical trials to clinical observations of children and
adults living with HIV has provided new insights into the
management of HIV including consideration for treatment
interruptions. Well-planned and monitored treatment interruptions can provide medical providers with the opportunity
to reduce long-term ARV drug toxicity, increased adherence,
and quality of life. Specifically for pediatric HIV management, studies in children have shown that high proportion
of children (30%) undergo treatment interruptions in routine
clinical care. With proper parameters and close follow-up,
treatment interruption studies in children have demonstrated
that the long-term immunological and virological outcomes
are similar among those who underwent treatment interruptions compared to children on continuous ART. Some recent
literature in adults has also demonstrated success for planned
and well-managed treatment interruptions in adults with a
baseline high CD4 cell count, high nadir CD4 cell count,
and a low HIV RNA viral load. Collectively, recent studies
in children and adults suggest that treatment interruptions
with proper monitoring can be considered as an alternative
treatment strategy by instituting parameters to identify lowrisk populations of treatment failure.

Key points

• Treatment interruptions can be favorable in pediatric and
adult populations with well-controlled human immunodeficiency virus (HIV) disease and intact immune systems.
• Planned treatment interruptions may increase adherence
while minimizing drug toxicity and improving quality of
life.
• In the pediatric populations, specifically, treatment interruptions have produced better outcomes compared to
adult populations and may represent an alternative HIV
management strategy during certain developmental stages.
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